EU/EMA Drug Approvals for upadacitinib

Subscribe to access the full database, or Start Trial
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Rinvoq	upadacitinib	EMEA/H/C/004760Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.	Authorised	no	no	no	2019-12-16
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

Last updated: July 8, 2026

Upadacitinib (UPA; brand: Rinvoq) is a blockbuster JAK inhibitor with sustained revenue growth driven by expansion across inflammatory indications and shift in payer mix toward maintenance use. The financial trajectory is now dominated by (1) label expansion into additional disease segments, (2) utilization management outcomes versus competing JAKs, IL-17/IL-23 pathways, and biologic TNF inhibitors, and (3) patent and exclusivity timelines that determine generic or biosimilar entry risk in the US and key ex-US markets.

Core business read-through: UPA’s commercial engine is broader than the initial RA launch, but the competitive and IP clock accelerates as key US composition-of-matter and formulation protections approach expiration, with settlement-driven “at-risk” timing effects typical of the JAK class.

What is upadacitinib’s market size, revenue trajectory, and growth drivers?

Upadacitinib’s commercial path tracks two forces: indication breadth and payer acceptance in chronic maintenance. The revenue profile has typically moved with: (a) new FDA label approvals and guideline adoption, (b) uptake into biologic-experienced and biologic-naïve segments, and (c) dosing consistency (standard fixed dosing schedules with predictable adherence patterns).

How do indications map to revenue momentum for Rinvoq?

UPA’s revenue mix historically skews toward high-incidence, high-need chronic inflammatory diseases where JAK inhibitors have strong penetration:

Rheumatoid arthritis (RA)
Psoriatic arthritis (PsA)
Ankylosing spondylitis (AS)
Non-radiographic axial spondyloarthritis (nr-axSpA)
Ulcerative colitis (UC)
Crohn’s disease (CD)
Atopic dermatitis (AD)
Juvenile idiopathic arthritis categories (where applicable by label)
Other inflammatory expansions depending on current approvals

Label breadth matters because each new indication adds incremental prescriber sets, payer coverage windows, and spend pools in both commercial and PBM channels.

What payer and channel dynamics most affect net sales?

Market dynamics for UPA in the US and major E5 markets are shaped by:

PBM formulary placement and prior authorization policies in chronic immunology
Contracted rebates tied to market share and clinical endpoints
Channel mix shift from induction to maintenance use across UC and CD
Step therapy versus biologics for RA/PsA/AS cohorts
Competition-driven price pressure in mature segments (RA and AS are typically most exposed)

How competitive forces influence utilization and pricing

UPA faces direct class competition from other JAK inhibitors and indirect competition from biologics and pathway-specific agents:

Direct JAK: tofacitinib, baricitinib, filgotinib (availability varies by geography), and other pipeline-to-market JAKs depending on region
Indirect: IL-17/IL-23 for psoriasis/axSpA; TNF inhibitors and IL-12/23 or IL-6 pathways for some GI inflammatory uses

In practice, net sales growth depends less on headline list price and more on negotiated net pricing, persistence, and switching behavior when safety or efficacy perception shifts.

How does Rinvoq’s financial performance compare with other JAK inhibitors?

Competitive comparisons generally show that the highest-performing JAK franchises combine broad label coverage with faster payer normalization in high-volume indications like RA and AD. UPA’s competitive position is usually anchored by:

Sustained uptake in multiple ILD and GI categories where payer restrictions can soften after early volume capture
Clinician preference for JAK class dosing simplicity versus infusion biologics
Case-by-case switching: patients move between JAKs based on safety profile perceptions, response kinetics, and plan incentives

Where does upadacitinib typically outperform on market penetration?

Chronic, maintenance-heavy indications where oral therapy improves continuity
Patient segments that already accept small-molecule immunomodulators
Markets where contracting or managed formularies favor JAK class agents

Where is financial exposure highest to competitive erosion?

Highly tender or aggressive PBM segments where competitors offer tighter rebates
Indications with multiple mechanism-of-action alternatives (notably RA and psoriatic disease spaces)
Segments where comparative effectiveness narratives shift rapidly after post-marketing safety updates across the JAK class

When does upadacitinib lose exclusivity in the US and key ex-US markets?

A realistic commercialization model for UPA depends on a US composition-of-matter-driven exclusivity timeline, possible pediatric extensions, and patent term adjustments. The generic entry risk is further modulated by:

Patent thickets in formulations and crystalline forms
Method-of-use claims for specific indications
Settlement outcomes that can delay Paragraph IV generics
Broad multi-jurisdiction filing strategies by the brand and challengers

What does “exclusivity” mean in practice for generic timing?

For small-molecule drugs like UPA, generic timing is typically constrained by:

US patent expiry (composition, polymorph, salts, and formulation patents)
Non-patent exclusivity such as FDA exclusivity periods (where applicable; not always the binding constraint for small molecules)
Orange Book-listed patents that block FDA approval until resolution or expiry
Triggering events such as a first applicant’s Paragraph IV filing and any associated settlement

What is the Orange Book status of upadacitinib, and how many patents cover it?

The Orange Book status determines which listed patents a generic applicant must address via Paragraph IV certifications or litigation. For UPA, the practical business question is the density and type of Orange Book coverage:

Composition-of-matter patents
Formulation patents (e.g., release characteristics, excipient systems, tablet properties)
Polymorph/crystal form patents
Method-of-use patents tied to specific indications and dosing regimens

How many patent families usually block generic entry for small-molecule JAK inhibitors?

For blockbuster JAK inhibitors, brands typically build multi-year thickets using overlapping claims across:

Core compound coverage
Salt/form selection and solid state form control
Formulation or manufacturing method claims
Use claims in specific immune-mediated indications

The commercial implication is that even if one composition-of-matter patent expires, remaining listed patents can delay “walk-up” generic approvals.

What patent estate protects upadacitinib’s formulations and dosing regimen?

Formulation and solid-state patents can be a major driver of “late-stage” IP barriers. For UPA, the relevant business buckets are:

Tablet formulation and excipient composition
Solid-state form control (polymorph/crystal type)
Manufacturing method constraints
Stability and dissolution-related claims that may require brand-validated specs

What formulations are typically protected for upadacitinib?

UPA is marketed as oral tablets with multiple dose strengths. Patent coverage commonly extends to:

Specific dose-strength formulations
Common excipient systems and compression parameters
Release and dissolution behavior targets

How does formulation patent coverage affect generic design?

Generic applicants can be forced into expensive reformulation cycles if:

Brand patents claim specific dissolution profiles or solid-state characteristics
Orange Book listing includes formulation claims for one or more dose strengths
Patent litigation narrows design-around options

What method-of-use patents apply to upadacitinib’s indications?

Method-of-use claims matter when a generic can engineer around composition and formulation barriers but remains blocked by use-specific claims tied to:

RA, PsA, AS, nr-axSpA treatment
UC and CD dosing regimens and endpoints
AD treatment and associated patient subsets

How do method-of-use claims influence Paragraph IV strategy?

A generic filer may:

Certify non-infringement or invalidity for only some patents
Challenge method-of-use claims linked to a subset of indications
Launch with limited label scope, depending on certification and litigation posture

Which companies have challenged upadacitinib patents via Paragraph IV?

Paragraph IV challenges are the key event for launch timing. The competitive and investment significance comes from:

First-filer settlement vs trial outcomes
Whether challenges target composition, formulation, or method-of-use patents
Whether a settlement includes “no-ATV” (no early at-risk launch) provisions until a defined date

This segment requires exact Orange Book listing, cert dates, court dockets, and settlement terms, none of which are present in the provided material.

What upadacitinib patent litigation affects generic entry, and what are settlement timelines?

In the US, patent litigation for blockbuster small molecules usually drives one of three outcomes:

Brand wins at preliminary injunction stage or on merits, blocking entry through expiry
Settlement delays generic launch until a negotiated date
Court invalidates or finds non-infringement for specific claims, enabling earlier approval

This analysis depends on case caption-level facts: asserted patents, final judgment dates, and settlement agreement effective dates. Those details are not included in the provided material.

What generic entry risks exist for upadacitinib in the US?

Generic entry risk is a function of:

Remaining enforceable Orange Book patents at the time of first generic approval
Strength of the brand’s infringement and validity positions in the most relevant patent subset
Whether challengers can design around solid-state/formulation claims
Whether settlements block at-risk entry

What do “generic risk” scenarios typically look like?

For drugs like UPA, the generic scenarios commonly modeled by investors are:

Delayed entry due to thicket settlements
Partial barrier, where some patents fall and generic launches with label carve-outs
Full entry at or shortly after patent expiry if method-of-use claims are weak or expired

A credible risk model requires Orange Book patent expiry mapping and litigation docket timelines, which are not included in the provided material.

How does upadacitinib compare with alternative therapies for the same indications?

From a commercial dynamics perspective, UPA’s main competitor landscape varies by indication:

RA and PsA/AS: other JAKs and TNF inhibitors/IL-6 or IL-17 pathway agents
UC/CD: anti-TNF, vedolizumab class (mechanism dependent), and IL-12/23 or integrin pathway agents in selected cohorts
AD: IL-4/IL-13 pathway agents and other targeted immunomodulators

What drives switching to upadacitinib?

Oral convenience and patient preference
Rapid symptom control narratives within class
Plan incentives and formulary placement
Prior biologic failure where JAKs show clinical preference in practice

What drives switching away from upadacitinib?

Safety perception shifts
Emergence of more favorable comparative efficacy narratives by competitor agents
Increased payer restrictions or tighter step edits

What is the FDA regulatory status of upadacitinib and how does it affect market access?

FDA approval status impacts:

Label scope for each indication
Dosing and contraindication messaging
Risk evaluation and mitigation program requirements (if any)
Post-marketing changes affecting prescribing behavior and formulary acceptance

However, an accurate financial trajectory linkage requires the current list of FDA approvals, any label revisions, and REMS or safety communication history. Those specifics are not provided in the material.

Key takeaways for market and financial planning

Upadacitinib’s revenue trajectory is driven by multi-indication expansion and long-term maintenance utilization, with payer contracting and step edits determining net growth more than list pricing.
Competitive pressure concentrates in mature indications where multiple mechanisms-of-action compete for the same payer dollars and patient cohorts.
Generic entry timing is governed by the Orange Book patent thicket and any Paragraph IV challenges or settlements. Without patent-expiry and litigation dataset details, the exclusivity-to-launch mapping cannot be stated.
For business planning, the highest-leverage variables to monitor are formulary wins, persistence in maintenance therapy, and any post-marketing safety or label tightening that changes switch behavior.

FAQs

What indications contribute most to upadacitinib’s long-term revenue retention?
How do PBM formularies and prior authorization requirements shift upadacitinib net pricing?
Which class competitors most affect Rinvoq market share in RA and psoriatic disease?
What patent categories (composition, formulation, method-of-use) typically delay generic upadacitinib entry?
How do US Paragraph IV challenges and settlements translate into launch delay windows for small-molecule immunology drugs?

References (APA)

[No cited sources were provided in the user prompt.]

International Patents:	233
US Patents:	45
Tradenames:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	85
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for upadacitinib
What excipients (inactive ingredients) are in upadacitinib?	upadacitinib excipients list
DailyMed Link:	upadacitinib at DailyMed

Sponsor	Phase
University of California, San Francisco	PHASE4
Berinstein, Jeffrey	PHASE4
Sint Maartenskliniek	PHASE4

Applicant	Application No.	Strength	Dosage Form
⤷ Start Trial	⤷ Start Trial	15MG	TABLET, EXTENDED RELEASE
⤷ Start Trial	⤷ Start Trial	30MG	TABLET, EXTENDED RELEASE
⤷ Start Trial	⤷ Start Trial	30MG	TABLET;ORAL

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RINVOQ LQ	Oral Solution	upadacitinib	1 mg/mL	218347	1	2026-03-02
RINVOQ	Extended-release Tablets	upadacitinib	45 mg	211675	3	2023-08-16

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	RINVOQ LQ	upadacitinib	SOLUTION;ORAL	218347-001	Apr 26, 2024		RX	Yes	Yes	11,661,425	⤷ Start Trial		Y		⤷ Start Trial
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-002	Jan 14, 2022		RX	Yes	No	11,564,922	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Country	Patent Number	Title	Estimated Expiration
Australia	2016340167		⤷ Start Trial
Australia	2020359635		⤷ Start Trial
Australia	2021236570		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506716	C02506716/01	Switzerland	⤷ Start Trial	PRODUCT NAME: UPADACITINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67257 20.01.2020
2506716	723	Finland	⤷ Start Trial
2506716	12/2020	Austria	⤷ Start Trial	PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 (MITTEILUNG) 20191218
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Summary for upadacitinib

Recent Clinical Trials for upadacitinib

Generic filers with tentative approvals for UPADACITINIB

Pharmacology for upadacitinib

Anatomical Therapeutic Chemical (ATC) Classes for upadacitinib

Paragraph IV (Patent) Challenges for UPADACITINIB